Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10378465 | 0.89 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL14972583 | 0.89 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL12136331 | 0.88 | TAAR1 (0.55) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL7901300 | 0.87 | ENPP2 (0.46) | TAAR1ALDH1A1CYP2D6HRH3ENPP2 | |
| SCHEMBL7990214 | 0.86 | TAAR1 (0.53) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL8000063 | 0.85 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL7989614 | 0.85 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL7998439 | 0.85 | TAAR1 (0.52) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL15432887 | 0.82 | TAAR1 (0.49) | TAAR1IDO1ALDH1A1CYP2D6HRH3 | |
| SCHEMBL29596752 | 0.82 | TAAR1 (0.74) | TAAR1IDO1HRH3MAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724714-A | Method for preparing 3-methoxyethyl-4-glycol monoformate vinyl toluene by palladium-catalyzed hydrocarbon activation | 浙江九洲药业股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118724714-A | Method for preparing 3-methoxyethyl-4-glycol monoformate vinyl toluene by palladium-catalyzed hydrocarbon activation | 浙江九洲药业股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118724714-A | Method for preparing 3-methoxyethyl-4-glycol monoformate vinyl toluene by palladium-catalyzed hydrocarbon activation | 浙江九洲药业股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-0146269-B1 | HETERO-POLYCYCLIC AROMATIC COMPOUND | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-01-03 | — | — | EP | disclosed |
| US-4650882-A | Dyes having two 5-membered lactone rings fused to a central cyclohexa-1.4-diene nucleus | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-03-17 | — | — | US | disclosed |
| EP-0146269-A2 | Hetero-polycyclic aromatic compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | TAAR1 2439/4885IDO1 953/4885ALDH1A1 1042/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TAAR1 2571/4885IDO1 270/4885ALDH1A1 709/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TAAR1 2571/4885IDO1 270/4885ALDH1A1 709/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TAAR1 2571/4885IDO1 270/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.